TriangleFOR PATIENTS · SOURCE READING
Treatment of Stage I and Stage II Mycosis Fungoides
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
NCI-linked patient version: mycosis fungoides and Sezary syndrome subset Patient source covers mycosis fungoides/Sezary syndrome; do not apply to all other cutaneous T-cell lymphomas.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of newly diagnosed stage I and stage II mycosis fungoides may include the following:
Psoralen and ultraviolet A (PUVA) radiation therapy.
Source links and citations
Ultraviolet B radiation therapy.
Source links and citations
Radiation therapy with total skin electron beam radiation therapy. In some cases, radiation therapy is given to skin lesions, as palliative therapy to reduce tumor size to relieve symptoms and improve quality of life.
Immunotherapy given alone or combined with therapy directed at the skin.
Source links and citations
Topical chemotherapy.
Source links and citations
Systemic chemotherapy with one or more drugs, which may be combined with therapy directed at the skin.
Source links and citations
Other drug therapy (topical corticosteroids, retinoid therapy, lenalidomide, histone deacetylase inhibitors).
Source links and citations
Targeted therapy (brentuximab vedotin).
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice